Acute migraine treatment: Patterns of use and satisfaction in a clinical population

Headache

Volumn 46, Issue 5, 2006, Pages 773-780

  Malik, Shahram N ^a   Hopkins, Mary ^a   Young, William B ^a   Silberstein, Stephen D ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Efficacy; Headache; Migraine frequency; Patterns; Satisfaction; Triptans

Indexed keywords

ACETYLSALICYLIC ACID; BARBITURIC ACID DERIVATIVE; CAFFEINE; ERGOT DERIVATIVE; ISOMETHEPTENE MUCATE; LONG ACTING DRUG; NARCOTIC ANALGESIC AGENT; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENOTHIAZINE DERIVATIVE; SHORT ACTING DRUG; STEROID; TRIPTAN DERIVATIVE;

ACADEMIC ACHIEVEMENT; ADULT; AFRICAN AMERICAN; AGED; CAUCASIAN; DEMOGRAPHY; DRUG EFFICACY; DRUG PREFERENCE; FEMALE; HEADACHE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; OUTPATIENT DEPARTMENT; PATIENT SATISFACTION; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENCE RISK; REVIEW; STATISTICAL ANALYSIS; TREATMENT RESPONSE;

ACETAMINOPHEN; ACUTE DISEASE; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CAFFEINE; DRUG COMBINATIONS; DRUGS, NON-PRESCRIPTION; ERGOTAMINE; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NARCOTICS; PATIENT SATISFACTION; QUESTIONNAIRES; RECURRENCE; SEROTONIN AGONISTS;

EID: 33646006350     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00437.x     Document Type: Review

References (43)

1. Henry P Migraine: Epidemiological data, repercussions on daily life and socioeconomic costs Pathol Biol (Paris) 2000 48 608 612
2. Solomon GD Price KL Burden of migraine. A review of its socioeconomic impact Pharmacoeconomics 1997 11 suppl 1 1 10
3. Lipton RB Stewart WF Prevalence and impact of migraine Neurol Clin 1997 15 1 13
4. Stewart WF Lipton RB Celentano DD Reed ML Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors JAMA 1992 267 64 69
5. Stewart WF Shechter A Rasmussen RK Migraine prevalence. A review of population-based studies Neurology 1994 44 S17 S23
6. Ferrari MD Migraine Lancet 1998 351 1043 1051
7. Lipton RB Diamond S Reed M Diamond ML Stewart WF Migraine diagnosis and treatment: Results from the American Migraine Study II Headache 2001 41 638 645
8. Lipton RB Stewart WF Diamond S Diamond ML Reed M Prevalence and burden of migraine in the United States: Data from the American Migraine Study II Headache 2001 41 646 657
9. Cady RK Diagnosis and treatment of migraine Clin Cornerstone 1999 1 21 32
10. Lipton RB Stewart WF VonKorff M The burden of migraine: A review of cost to society Pharm Econ 1994 6 215 222
11. Rozen TD Swanson JW Stang PE McDonnell SK Rocca WA Increasing incidence of medically recognized migraine headache in a United States population Neurology 1999 53 1468 1473
12. Stang PE Yamagihara T Swanson JW et al. Incidence of migraine headaches: A population-based study in Omstead County, Minnesota Neurology 1992 42 1657 1662
13. Morillo LE Alarcon F Aranaga N et al. Clinical characteristics and patterns of medication use of migraneurs in Latin America from 12 cities in 6 countries Headache 2005 45 118 126
14. Celentano DD Stewart WF Lipton RB Medication use and disability among migraineurs: A national probability sample Headache 1992 32 223 228
15. Lipton RB Scher AI Steiner TJ et al. Patterns of health care utilization for migraine in England and in the United States Neurology 2003 60 441 448
16. Wenzel RG Lipton RB Diamond ML Cady R Migraine therapy: A survey of pharmacists' knowledge, attitudes, and practice patterns Headache 2005 45 47 52
17. Lipton RB Scher AI Kolodner K Liberman J Steiner TJ Stewart WF Migraine in the United States: Epidemiology and patterns of health care use Neurology 2002 58 885 894
18. Wenzel RG Sarvis CA Krause ML Over-the-counter drugs for acute migraine attacks: Literature review and recommendations Pharmacotherapy 2003 23 494 505
19. Dahlof C Assessing patient preference in migraine treatment Cephalalgia 2001 21 791 795
20. Shikiar R Rentz AM Satisfaction with medication: An overview of conceptual, methodologic, and regulatory issues Value Health 2004 7 204 215
21. Acquadro C Berzon R Dubois D et al. Incorporating the patient's perspective into drug development and communication: An ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001 Value Health 2003 6 522 531
22. Hunter M Philips C Rachman S Memory for pain Pain 1979 6 35 46
23. Linton SJ Melin L The accuracy of remembering chronic pain Pain 1982 13 281 285
24. Linton SJ Gotestam KG A clinical comparison of two pain scales: Correlation, remembering chronic pain, and a measure of compliance Pain 1983 17 57 65
25. Stewart WF Lipton RB Simon D Liberman J Von Korff M Validity of an illness severity measure for headache in a population sample of migraine sufferers Pain 1999 79 291 301
26. Lipton RB Bigal ME Goadsby PJ Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review Cephalalgia 2004 24 321 332
27. Cady R Martin V Adelman J Diamond M Sajjan S Hu XH Migraine treatment with rizatriptan and non-triptan usual care medications: A pharmacy-based study Headache 2004 44 900 907
28. Chia YC Lim SH Wang SJ Cheong YM Denaro J Hettiarachchi J Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs Headache 2003 43 984 990
29. Solomon S Frishberg B Hu XH Markson L Berger M Migraine treatment outcomes with rizatriptan in triptan-naive patients: A naturalistic study Clin Ther 2001 23 886 900
30. Baos V Serrano A Torrecilla M et al. Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting Int J Clin Pract 2003 57 761 768
31. Diamond ML Hettiarachchi J Hilliard B Sands G Nett R Effectiveness of eletriptan in acute migraine: Primary care for Excedrin nonresponders Headache 2004 44 209 216
32. Tfelt-Hansen P Block G Dahlof C et al. Guidelines for controlled trials of drugs in migraine 2nd edn Cephalalgia 2000 20 765 786
33. Gallagher RM Kunkel R Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment Headache 2003 43 36 43
34. Cady RK Lipton RB Hall C Stewart WF O'Quinn S Gutterman D Treatment of mild headache in disabled migraine sufferers: Results of the Spectrum Study Headache 2000 40 792 797
35. Pascual J Clinical benefits of early triptan therapy for migraine Headache 2002 42 suppl 1 10 17
36. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group Headache 1998 38 173 183
37. Klapper JA Rosjo O Charlesworth B Jergensen AP Soisson T Treatment of mild migraine with oral zolmitriptan 2.5 mg provides high pain free response rates in patients with significant migraine related disability Neurology 2002 58 suppl 3 A416 Abstract
38. Davies GM Santanello N Lipton R Determinants of patient satisfaction with migraine therapy [In Process Citation] Cephalalgia 2000 20 554 560
39. Lipton RB Hamelsky SW Dayno JM What do patients with migraine want from acute migraine treatment? Headache 2002 42 suppl 1 3 9
40. Marcus DA Establishing a standard of speed for assessing the efficacy of the serotonin (1B/1D) agonists (triptans) Arch Neurol 2001 58 1056 1058
41. Leinisch-Dahlke E Akova-Ozturk E Bertheau U Isberner I Evers S May A Patient preference in clinical trials for headache medication: The patient's view Cephalalgia 2004 24 347 355
42. Mueller L Gallagher R Which clinical measures of triptan efficacy best correlate with patient satisfaction in a disabled population? Cephalalgia 2005 807 Abstract
43. Silberstein SD Migraine symptoms: Results of a survey of self-reported migraineurs Headache 1995 35 387 396